Keryx seeks FDA OK for Zerenex for hyperphosphatemia in CKD; MAA soon
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals' submission of a new drug application (NDA) to the US FDA for Zerenex (ferric citrate coordination complex) as treatment for elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis had investors driving shares up about 2% early in the trading day on 8 August.